FIGURE 5.
(A) Progression‐free survival of patients prior treated with (n = 44) and without (n = 128) lapatinib; (B) Progression‐free survival of patients with (n = 141) and without (n = 31) visceral metastases.
(A) Progression‐free survival of patients prior treated with (n = 44) and without (n = 128) lapatinib; (B) Progression‐free survival of patients with (n = 141) and without (n = 31) visceral metastases.